Preexisting immunity to poliovirus does not impair the efficacy of recombinant poliovirus vaccine vectors

Journal of Virology

Volumn 75, Issue 2, 2001, Pages 622-627

  Mandl, S ^a   Hix, L ^a   Andino, R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLIOMYELITIS VACCINE; RECOMBINANT VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNIZATION; MOUSE; NONHUMAN; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; VIRUS IMMUNITY; VIRUS RECOMBINANT;

ANIMALS; ANTIBODIES, VIRAL; GENETIC VECTORS; IMMUNIZATION, SECONDARY; MELANOMA; MICE; OVALBUMIN; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VACCINES, SYNTHETIC;

EID: 0035167054     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.2.622-627.2001     Document Type: Article

References (32)

1. Polioviruses containing picornavirus type 1 and/or type 2 internal ribosomal entry site elements: Genetic hybrids and the expression of a foreign gene
2. Engineering poliovirus as a vaccine vector for the expression of diverse antigens
3. Protective efficacy of a recombinant vaccinia virus in vaccinia-immune mice
4. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity
5. Poliovirus mutant that does not selectively inhibit host cell protein synthesis
6. Antigen chimeras of poliovirus as potential new vaccines
7. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein
8. Mucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: Stimulation of humoral, mucosal, and cellular immunity
9. Inhibition of endoplasmic reticulum-to-Golgi traffic by poliovirus protein 3A: Genetic and ultrastructural analysis
10. Inhibition of cellular protein secretion by poliovirus proteins 2B and 3A
11. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity
12. Studies on the development of natural immunity to poliomyelitis in Louisiana
13. Vaccination with two different vaccinia recombinant viruses: Long-term inhibition of secondary vaccination
14. Poliovirus vaccine vectors elicit antigen-specific cytotoxic T cells and protect mice against lethal challenge with malignant melanoma cells expressing a model antigen
15. Attenuated poliovirus strain as a live vector: Expression of regions of rotavirus outer capsid protein VP7 by using recombinant Sabin 3 viruses
16. Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastasis
17. Poliomyelitis and poliovirus immunization
18. Introduction of soluble protein into the class I pathway of antigen processing and presentation
19. New approaches for mucosal vaccines for AIDS: Encapsidation and serial passages of poliovirus replicons that express HIV-1 proteins on infection
20. The effect of pre-existing adenovirus-specific immunity on immune responses induced by recombinant adenovirus expressing glycoproteinD of bovine herpes type 1
21. Inactivated polio vaccine
22. Immunization of mice with poliovirus replicons expressing the C-fragment of tetanus toxin protects against lethal challenge with tetanus toxin
23. Transgenic mice expressing a human poliovirus receptor: A new model for poliomyelitis
24. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: Long-term protection and effect of revaccination
25. Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer
26. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen
27. Live attenuated poliovirus vaccines
28. Toward a poliovirus-based simian immunodeficiency virus vaccine: Correlation between genetic stability and immunogenicity
29. Viruses use stealth technology to escape from the host immune system
30. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung
31. Poliovirus recombinants expressing hepatitis B virus antigens elicited a humoral immune response in susceptible mice